Wegovy, now in a pill.
The Wegovy pill is Novo Nordisk's oral form of semaglutide — the same active medicine as the Wegovy injection, taken as a once-daily tablet instead of a weekly injection. It has been authorised by the MHRA, and we expect it to reach UK patients from around July 2026 — possibly sooner.
The same medicine, in a tablet.
The Wegovy pill contains semaglutide — exactly the same active ingredient as the Wegovy and Ozempic injections. The difference is the delivery: instead of a once-weekly injection, it's taken as a once-daily tablet.
Semaglutide is a peptide, which would normally be broken down in the stomach. To make an oral version possible, Novo Nordisk pairs it with an absorption enhancer (the same technology used in their existing oral tablet, Rybelsus) so enough of the medicine is absorbed from a tablet.
It works on the same gut-hormone pathway as the injections: activating the GLP-1 receptor to reduce appetite, slow stomach emptying and improve blood-sugar control. The maintenance dose is a 25 mg tablet once daily, reached by stepping up gradually over a few months. Like the existing oral semaglutide tablet, it must be taken first thing in the morning on an empty stomach, with a small sip of plain water, and nothing else to eat, drink or take for at least 30 minutes — that timing is needed for the medicine to absorb properly.
Where we are on the timeline.
The Wegovy pill is the oral form of a medicine the UK already knows well. Here's where it sits on the path to UK availability.
Wegovy pill regulatory timeline
- Phase 3 — OASIS programme Trials completed. Novo Nordisk's OASIS trials report positive weight-loss and safety data for oral semaglutide.
- 11 June 2026 MHRA approval. The UK medicines regulator authorises Wegovy pill (semaglutide tablets) for weight management in adults with obesity (BMI ≥30), or overweight (BMI ≥27) with a weight-related condition — the UK's first daily oral GLP-1 weight-loss pill.
- Now Awaiting UK launch & supply. Approval is the green light; stock and a launch date follow. The Weight Clinic is getting its pathway ready so we can prescribe it as soon as it's available.
- From July 2026 — possibly sooner Expected UK private availability. The Wegovy pill is expected to reach UK patients on private prescription from around July 2026, possibly sooner. The Weight Clinic plans to be among the first to offer it.
- Later (uncertain) NHS access. At launch the Wegovy pill is available on private prescription only — it is not on the NHS. A separate NICE appraisal would be needed before any routine NHS use.
The same medicine is available today.
You don't have to wait. The Wegovy pill is the tablet form of semaglutide — and the Wegovy injection, the identical active ingredient, is already UK-licensed and available through us. If you'd prefer the strongest weight-loss option, Mounjaro (tirzepatide) is licensed too.
Available now: Wegovy injection
- Same medicine: semaglutide — identical active ingredient to the pill
- Form: once-weekly injection (the pill is once-daily)
- Status: UK-licensed and available through The Weight Clinic today
- Also licensed: Mounjaro (tirzepatide), the highest average weight loss of the licensed injections
Or: register interest in the pill
If you'd specifically prefer the Wegovy pill when it launches, let us know. We'll email you once it's available for us to prescribe in the UK. We won't use your email for anything else, and you can unsubscribe at any time.
Register interest →What people are asking us.
Will it cost less than the injection?
Pricing for the Wegovy pill in the UK hasn't been published yet. It will depend on the launch terms and supply. We'll publish pricing the day we're able to start prescribing it.
Is the pill as effective as the injection?
Both the pill and the injection contain semaglutide and work on the same GLP-1 pathway. In trials the oral form produced clinically meaningful weight loss. Your clinician will advise which is most appropriate for you.
Are the side effects different?
Like the Wegovy and Mounjaro injections, the most common side effects in trials were nausea, vomiting, diarrhoea, constipation and reduced appetite — usually mild to moderate and easing within a few weeks of starting or increasing the dose.
Want to know the moment it launches?
Drop us a note via the contact form, mentioning the Wegovy pill. We'll email you the day we're able to prescribe it. In the meantime, our clinician consultation is available for the UK-licensed alternatives — including the same medicine as an injection.